|
| 36302172 | Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response. | Clin Cancer Res | 2023 |
| 37509240 | MRI Apparent Diffusion Coefficient (ADC) as a Biomarker of Tumour Response: Imaging-Pathology Correlation in Patients with Hepatic Metastases from Colorectal Cancer (EORTC 1423). | Cancers (Basel) | 2023 |
| 37922931 | A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis. | Lancet Oncol | 2023 |
| 35833413 | Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) Results. | Ann Surg | 2023 |
| 36829145 | Statistical models versus machine learning for competing risks: development and validation of prognostic models. | BMC Med Res Methodol | 2023 |
| 36116829 | New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas. | Eur J Cancer | 2022 |
| 35481400 | Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'. | Acta Oncol | 2022 |
| 35401025 | Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. | Sarcoma | 2022 |
| 35536104 | Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092-22092 STRASS trial. | Cancer | 2022 |
| 35561319 | First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. | Cancer | 2022 |
| 36424032 | Imaging endpoints for clinical trial use: a RECIST perspective. | J Immunother Cancer | 2022 |
| 35980618 | Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). | JAMA Oncol | 2022 |
| 34333446 | The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy. | Eur J Cancer | 2021 |
| 33765967 | Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. | BMC Cancer | 2021 |
| 34301749 | Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. | Clin Cancer Res | 2021 |
| 34298376 | Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. | Eur J Cancer | 2021 |
| 34062484 | Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA". | Eur J Cancer | 2021 |
| 32129883 | Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. | Cancer | 2020 |
| 32083990 | Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. | J Clin Oncol | 2020 |
| 33121537 | iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study. | Cancer Imaging | 2020 |
| 32944214 | Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study. | Clin Sarcoma Res | 2020 |
| 32941794 | Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2020 |
| 32767667 | Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals. | Cancer | 2020 |
| 32847839 | Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. | ESMO Open | 2020 |
| 32470848 | Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. | Eur J Cancer | 2020 |
| 32236507 | Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. | JAMA Surg | 2020 |
| 30690293 | The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. | Eur J Cancer | 2019 |
| 31479947 | Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study. | Eur J Cancer | 2019 |
| 30860949 | RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. | J Clin Oncol | 2019 |
| 30831041 | Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. | Acta Oncol | 2019 |
| 30765389 | Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. | Clin Cancer Res | 2019 |
| 28929359 | Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. | Breast Cancer Res Treat | 2018 |
| 29893791 | Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. | Ann Oncol | 2018 |
| 30349653 | Surrogate endpoints in advanced sarcoma trials: a meta-analysis. | Oncotarget | 2018 |
| 29550245 | European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. | Clin Oncol (R Coll Radiol) | 2018 |
| 29521151 | Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. | Acta Oncol | 2018 |
| 29383713 | Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). | Int J Cancer | 2018 |
| 29574364 | Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. | Eur J Cancer | 2018 |
| 29435853 | Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial. | Breast Cancer Res Treat | 2018 |
| 29656586 | Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. | Cancer Med | 2018 |
| 29650688 | Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. | Oncologist | 2018 |
| 29307568 | A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. | Semin Cancer Biol | 2018 |
| 29092024 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Ann Oncol | 2018 |
| 27995946 | RECIST - learning from the past to build the future. | Nat Rev Clin Oncol | 2017 |
| 28111876 | Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). | Pediatr Blood Cancer | 2017 |
| 28362562 | Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. | J Clin Oncol | 2017 |
| 28431480 | Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. | Acta Oncol | 2017 |
| 28477490 | Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. | Eur J Cancer | 2017 |
| 28271869 | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. | Lancet Oncol | 2017 |
| 27838944 | Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. | Acta Oncol | 2017 |